Comparing Eloxx Pharmaceuticals and Finch Therapeutics Group

A look at the revenue, earnings, and valuation of these two biotech firms.

Published on Feb. 8, 2026

Got story updates? Submit your updates here. ›

This article compares the financial metrics and business profiles of Eloxx Pharmaceuticals and Finch Therapeutics Group, two clinical-stage biopharmaceutical companies focused on developing novel treatments for rare and ultra-rare diseases.

Why it matters

The comparison provides insight into the relative financial positions and growth prospects of these two emerging biotech firms, which could be of interest to investors and industry observers tracking developments in the rare disease treatment space.

The details

The article notes that Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating it may be the more affordable of the two stocks currently. It also highlights that Eloxx Pharmaceuticals has a much higher beta, suggesting its stock price is significantly more volatile than the broader market. The piece outlines the core focus areas and product pipelines for each company, with Eloxx developing treatments for conditions like cystic fibrosis and Finch working on therapies for autism spectrum disorder and inflammatory bowel diseases.

  • The article was published on February 8, 2026.

The players

Eloxx Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing ribosome modulation treatments for rare and ultra-rare premature stop codon diseases.

Finch Therapeutics Group

A clinical-stage microbiome therapeutics company developing a novel class of orally administered biological drugs, including treatments for autism spectrum disorder and inflammatory bowel diseases.

Got photos? Submit your photos here. ›

The takeaway

This comparison highlights the differing financial profiles and product pipelines of Eloxx Pharmaceuticals and Finch Therapeutics Group, two promising biotech firms operating in the rare disease treatment space. Investors and industry observers will likely continue to monitor the progress of each company's clinical programs and financial performance in the months and years ahead.